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Summary Tumours with high somatic mutation rates
escape immune surveillance by upregulating recep-
tors and ligands such as programmed death receptor-
1 and its ligand (PD-1/PD-L1). Checkpoint inhibitors
(ICI) provide encouraging therapeutic results in non-
small cell lung cancers (NSCLC) andmay soon be used
in 2nd or 1st line therapy. Currently PD-L1 immuno-
histochemistry (IHC) expression assessed on tumour
cells is used as a predictive biomarker, since better
patient outcomes are often, but not always associ-
ated with increased tumour cell PD-L1 IHC expres-
sion. However pre-analytical variables, different anti-
PD-L1 clones used on different staining platforms, dif-
ferent specimens types, as well as intra- and interob-
server variability influence the results. We will only
understand PD-L1 expression on tumour cells if we
accept that PD-L1 is an inducible pathophysiologi-
cal factor with variable levels of PD-L1 expression de-
pending on the immunological status. Should we test
PD-L1 during initial diagnostic work up before, or at
the point when immune checkpoint therapy is con-
sidered? Taking all arguments into account the value
of PD-L1 as a predictive biomarker is questionable.
Other predictive biomarkers such as high mutation
burden, mRNA expression, neo-antigens and the di-
versity of tumour antigen-specific T cells should be
evaluated in the future. Here we review results pre-
sented in 30 journal articles and three reviews cover-
ing this topic in the last 3 years.
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Immune receptors and ligands
Within their microenvironment tumour cells can
modify the immune response, which comprises a dy-
namic balance of multifactorial interactions with
stimulating and inhibitory receptors and ligands of
immune cells. The same mechanisms help create
immune tolerance and prevent autoimmune diseases
[1]. Particularly tumours with a high rate of somatic
mutations such as lung cancers or melanomas are
immunogenic [2–5]. They induce upregulation of re-
ceptors and ligands such as the programmed death
receptor-1 and its ligand (PD-1/PD-L1) and B7/CTLA-
4, and consequently they escape immune surveil-
lance. Checkpoint inhibitors, especially monoclonal
antibodies against PD-1 and its ligand PD-L1 have
proven to provide a promising therapeutic approach
in non-small cell lung cancer (NSCLC) [1, 6–10].
PD-L1 IHC expression as a predictive biomarker
Today numerous PD-1 inhibitors are available such as
nivolumab (Opdivo, Bristol Myers Squibb, NY, USA)
and pembrolizumab (Keytruda, MSD, Kenilworth, NJ,
USA) or PD-L1 inhibitors such as durvalumab (As-
taZeneca, London, UK), atezolizumab (Roche, Basel,
Switzerland) and avelumab (Pfizer/Merck Serono,
Berlin/Darmstadt, Germany). Since checkpoint in-
hibitors may be used in 2nd or 1st line therapy in the
near future, it is important to define a reliable pre-
dictive biomarker. One candidate is the expression
of PD-L1 assessed by immunohistochemistry (IHC)
especially on tumour cells [5, 7]. A number of PD-L1
antibody clones are available as prepackaged kits or
as free antibodies, using different staining platforms
and different staining protocols as well as different
scoring systems and different cut offs for predictive
evaluation (Table 1; [7]). They can be used on Ventana
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cdepending on the ICI used
PD-L1 programmed death ligand, ICI immune checkpoint inhibitor, TC tumour cells, IC immune cells
Ultra Systems, DAKO Autolink 48 stainers or others
with or without enhancement systems (Figs. 1 and 2).
Is there an optimal threshold?
The results of “The Blueprint PD-L1 IHC Assay Com-
parison Project”, a phase I study, were presented by
Dr. Hirsch et al. at the recent 2016 Annual Meeting of
the AACR. In this study three of four assays were an-
alytically similar for tumour cell staining, i. e. SP263,
28-8 and 22C3, but no clinical diagnostic cut-off was
applied in the project. At the same AACR meeting,
M. Ratcliffe presented “A Comparative Study of PD-
L1 Diagnostic Assays”. Evaluating 500 biopsy samples
including both squamous and non-squamous histol-
ogy and showed that a 25% cut-off point using Ven-
tana SP263 was similar to the results obtained from
a DAKO 28-8 test at 10% cut-off mark. The results
from the SP263 and the Dako 22C3 tests were similar
at a cut-off of 50%. All three tests agreed overall in
more than 90% of cases.
In a review by Kerr et al. [6], the calculated rate
of positivity in 10 analysed studies for PD-L1 was be-
tween 13 and 70%[11–14] and the correlation between
treatment and biomarker response rate was given as
13–83% depending upon the cut-offs, the specific an-
tibody clones as well as the therapeutic agent used
[7, 15]. Tumour proportion scores (TPS) were defined
as the percentage of tumour cells with complete or
partial membranous staining at any intensity. A wide
range of cut-off points determined IHC positivity with
values of 1, 5, 10, 25 and 50% [11, 16–18]. Commonly
high expression of PD-L1 indicates a better therapy
response [5, 7, 13, 16, 19–23] and showed improv-
ing hazard ratios for overall survival (OS) and progres-
sion free survival (PFS) with increasing levels of PD-
L1 staining [24]. Nevertheless many studies also re-
port significant response rates (3–20%) in PD-L1 IHC-
negative cases [6, 12, 15, 25].
Khunger et al. presented “Meta-analysis of tumour
PD-L1 expression as a predictive biomarker of benefit
from PD-1/PD-L1 axis inhibitors in solid tumours” at
ASCO 2016. The analysis evaluated 18 studies with
2731 patients. Inclusion criteria were different tu-
mours with high mutational burden, with 9 studies of
NSCLC with known IHC PD-L1 status and PD1/PDL1
inhibitor treatment. A threshold of 5% PD-L1 IHC ex-
pression was highly predictive for different drugs as
nivolumab, pembrolizumab, atezolimumab, durval-
umab and avelumab. The largest therapeutic effect
was seen in NSCLC (OR = 3.33; 95% CI 2.52–4.40, p <
0.001). The authors concluded that 5% tumour PD-
L1 expression as a threshold of PD-L1 expression may
be optimal.
Results of the phase III CheckMate057 study [12]
showed that PD-L1 IHC with a cut-off point of 1%
correlated with ORR and PFS in pretreated NSCLC.
Likewise Passiglia et al. [15] calculated a threshold of
1% for PD-L1 expression based on evaluating 7 stud-
ies with 914 patients with PD-L1 positive tumours.
These patients had a significantly higher ORR, than
patients with PD-L1 negative tumours (OR: 2.44; 95%
CI 1.61–3.68) [15].
Kerr et al. reported the use of different thresholds
in different biomarker studies using the example of
nivolumab [1, 5]. Trials of this agent used anti–PD-
L1 IHC antibody clone 28-8 (Dako, Glostrup, Den-
mark) with cut-off points of ≥1, ≥5 and ≥10% to define
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Fig. 1 Pulmonary adenocarcinoma. aHE andbpositive TTF1 staining, both images ×100 magnification
Fig. 2 Imagesof theTTF1+pulmonaryadenocarcinomaseen inFig.1stainedpositive withdifferentPD-L1antibodyclones, Cross-
testing, (a,b)Abcam28-8andCellSignalingE1L3Nand,bothstainedonVentanaUltrawithOptiView, (c,d)DAKOPharmDX22C3and
Ventana SP263, both prepackaged kits. Scoring does not evaluate intensity therefore enhancement systems such as OptiView can
be used without altering the results. All images ×100 magnification
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Table 2 PD-L1 scoring





IC score Description PD-L1 TC
staining (%)
TC score
IC ≥ 10 IC3 TC ≥ 50 TC3
IC ≥ 5 and <10 IC2 TC ≥ 5 and <50 TC2
IC ≥ 1 and <5 IC1 TC ≥ 1 and < 5 TC1
IC < 1 IC0 TC < 1 TC0
IC immune cells, TC tumour cells
positive staining [13]. Eventually, nivolumab was ap-
proved without the need for complementary diagnos-
tic. Biomarker tests for pembrolizumab used anti–PD-
L1 Dako clone 22C3 with two different cut-offs of ≥1%
and ≥50% in the conducted study to define positive
staining and for clinical use, ≥50% TPS was consid-
ered positive [20, 26, 27]. Meanwhile pembrolizumab
has been approved by the EMA with a cut-off point of
1% with any approved IHC test similar to 22C3. Dur-
valumab uses the anti–PD-L1 Ventana SP263 antibody
clone with a cut off of ≥25% [25].
PD-L1 testing on immune cells and/or tumour
cells
Azetolizumab with SP142 Ventana as a companion di-
agnostic requires assessment of TC and/or tumour-
associated immune cells (ICs) (Table 2; [23]).
Herbst et al. [4] showed that PD-L1 expression on
tumour infiltrating immune cells predicts responses
to atezolizumab better than PD-L1 expression on tu-
mour cells. Teng et al. reported that combining IHC
PD-L1 expression status of tumour-infiltrating lym-
phocytes and tumour cells might help to select pa-
tients for combination therapies [5, 28].
Biomarker expression in lymphoid or other im-
mune effector cells is a special challenge for patholo-
gists. Inter- and intra-observer bias for TILs is lower
than for tumour cells [28], the pathologist cannot
always recognize whether the existing lymphocyte
population is oncogene or inflammation driven [23,
28]. Scheel et al. showed that reproducible PD-L1
IHC scoring of tumour cells seems feasible whereas
scoring of immune cells did not yield reproducible
results [29].
The threshold that discriminates between therapy
responders and nonresponders should be calculated
from collected response data; however it is not clear
whether benefit from immunotherapy might be better
described by progression-free or overall survival data
than by overall response rate [3, 10, 16, 20]. Studies
suggest that traditional response criteria may not be
able to fully capture the immune-therapy activity [15].
Does heterogeneity of lung cancer influence
PD-L1 results?
PD-L1 expression results might not represent the true
PD-L1 status of a tumour due to the heterogeneity
of PD-L1 expression in lung cancer, this is especially
challenging if only biopsies are evaluated [1]. Kerr
and other authors [1, 5, 16] stated that in a multifac-
torial dynamic system reacting sensitive to changes,
any earlier form of chemotherapy or targeted therapy
may induce PD-L1 expression. The opposite was re-
ported by Herbst et al. in abstract 3030 ASCO 2016
“Archival vs new tumour samples for assessing PD-
L1 expression in the KEYNOTE-010 study”. The dis-
tribution of PD-L1 (TPS 1–49% and >50%) was sim-
ilar in archival and newly collected tumour samples
of patients with previously treated NSCLC. These data
suggest that a new tumour biopsy sample may not be
required at the time when ICI therapy is considered,
questioning the value of rebiopsy.
Does histology affect PD-L1 testing?
Patients with squamous cell carcinomas treated with
nivolumab did not show improvements in PFS and OS
dependent on the level of PD-L1 expression [3]. In pa-
tients with non-squamous cell carcinoma treated with
nivolumab or docetaxel, the nivolumab treated group
with positive PD-L1 IHC expression showedbetter PFS
and OFS [12]. Hence mainly tumours with non-squa-
mous histology should be tested for PD-L1 expression
in lung cancer.
Standardizing PD-L1 testing
PD-L1 tests must be reproducible, both the technical
procedure of staining and the interpretation of the test
by pathologists. Pre-analytical issues such as tissue
fixation and processing have a major impact on the
outcomes of immunohistochemical reactions [14, 21]
and might affect the results of different PD-L1 IHC
tests.
Standardization of these biomarker tests can be
reached by using exclusively prepackaged test kits
of reagents running on company-specific staining
platforms with an industry standard [24]. However
free antibody clones such as Abcam 28-8, Cell sig-
nalling E1L3N and others are less expensive than
their prepackaged counterparts and can be estab-
lished on different staining platforms without quality
impairment. The results obtained from cross testing
PD-L1 IHC 28-8 pharmDx on Autostainer Link 48
versus Anti-PD-L1 antibody 28-8 (Abcam) on Ventana
Ultra with OptiView in our department showed no sig-
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nificant differences in staining results (unpublished
data). Worldwide numerous cross-assay validations
and interlaboratory tests (round robin tests) are per-
formed to determine the reproducibility of PDL1 im-
munohistochemistry yet without having found a gold
standard.
Other predictive biomarkers
Upcoming biomarkers may include the high mutation
burden within the PD-L1 positive tumour cell group,
expression of neo antigens, the diversity of the T cell
repertoire and PD-L1 mRNA expression [30].
Conclusion
PD1/PD-L1 biology is complex with conflicting results
from different studies. Moreover PD-L1 IHC does not
fulfil the strict criteria of a biomarker as anaplastic
lymphoma kinase (ALK) translocation or epidermal
growth factor receptor (EGFR) mutation does. Nev-
ertheless PD-L1 IHC expression seems to be the best
currently available biomarker andmay be indicative of
a dose–response relationship between PD-L1 expres-
sion and drug efficacy. A low threshold such as a PD-
L1 TPS of 1% allows us to include nearly all patients
who may really benefit from these therapies. How-
ever, since it may be inappropriate to select patients
for ICI therapy solely on the basis of PD-L1 expression
other predictive biomarkers should be established. In
advanced lung cancer plasma PD-L1 protein could
provide a promising alternative for monitoring PD-
L1 levels. PDL1-enzyme linked immunosorbent as-
say (PDL1-ELISA) can analyse PDL1 quantitatively or
qualitatively in plasma and PDL1 western blot might
help to detect specific proteins in tissue homogenate.
Mutational findings from targeted NGS panels can be
correlated with response, but until today targeted NGS
panels were not able to predict response to check-
point inhibitors. Looking at DNA only provides lim-
ited information therefore, if we understand mRNA
as a molecule reflecting the dynamic nature of a can-
cer cell, we should focus on investigating the cancer
transcriptome in future.
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